糖尿病证候学特征及降糖补肾方对炎症标志物的作用研究
|
摘要
目前我国20岁以上的成年人糖尿病患病率为9.7%,我国成人糖尿病总数达9240万,约90%为2型糖尿病(type2diabetes mellitus, T2DM),糖尿病已经成为影响我国人民健康的主要公共卫生问题。中医学早在《灵枢·五变篇》即有“肾虚则善病消瘅”的记载,认为本病的发生于肾虚有密切关系,或曰肾虚是消渴发病的关键因素。在西医学的认识中近年来糖尿病的炎症学说得到越来越多业内专家学者的认可,本学说认为T2DM是一种慢性、亚临床性的炎症疾病,许多促炎症因子、双链RNA和病毒等通过作用于IKKβ而引起胰岛素抵抗(insulin resistance,IR)和胰岛β细胞凋亡,导致T2DM。IKKβ已成为防治T2DM研究的新的药理学作用靶点,抑制IKKβ的活性可以阻止T2DM及其并发症的发生发展。
前期的研究表明,中药复方降糖补肾方有补肾健脾,养阴清热之功效,临床治疗T2DM疗效较好,并证实该方能抑制炎症反应。本研究旨在了解2型糖尿病的临床特点及代谢特点,总结2型糖尿病的证候规律,对中医证候与炎症指标及其他实验室指标进行相关性分析,了解中医证候的物质基础。并在前期临床研究的基础上,深入探讨降糖补肾方治疗T2DM的作用机理,从炎症细胞因子作用的源头IKKβ/NF-κB通路入手,观察降糖补肾方对此通路的关键环节IKKβ表达及活性的干预作用。这一研究可能明确降糖补肾方具体作用环节,研究结果将为针对T2DM炎症生物效应靶点可能开发出预防和治疗T2DM的中药新药,从而产生客观的经济和社会效益。
目的：
1.通过2型糖尿病的相关文献研究,了解目前中西医对2型糖尿病炎症学说的认识,系统评价国内生物医学类期刊发表的补肾活血类中药复方治疗2型糖尿病的临床疗效及安全性。
2.通过临床观察了解2型糖尿病的临床特点及代谢特点,总结2型糖尿病的证候规律,了解2型糖尿病中医证候的物质基础。
3.通过实验研究了解中药复方降糖补肾方的疗效及具体作用环节。
方法：
1.文献研究
对近年来中西医对2型糖尿病炎症学说的认识进行文献综述,通过计算机检索建库-2011年5月国内生物医学类期刊发表的有关中医药补肾活血法治疗2型糖尿病的临床研究文献并对其临床疗效及安全性进行系统评价。
2.临床研究
广东省中医院内分泌科2011年3月至2011年6月门诊和内分泌科病房的2型糖尿病患者60例,搜集患者的一般人口学资料、西医相关指标、炎症因子指标、并发症及伴发疾病情况及中医证候积分,采用EPIdata3.1软件包建立数据库,spss17.0进行统计分析。
3.实验研究
采用高脂饲料喂养+小剂量链脲佐菌素腹腔注射的方法制备糖尿病大鼠模型,成模大鼠随机分组,并对各组大鼠予相应干预,检测各组大鼠的血糖水平、血清炎症因子水平、糖尿病大鼠肌肉组织的IKK β mRNA表达及糖尿病大鼠肌肉组织的InsR磷酸化蛋白水平、IRS-1酪氨酸磷酸化蛋白水平,采用spssl7.0软件包进行统计分析。
结果：
1.临床研究结果
(1)60例2型糖尿病患者的平均年龄为61.20±12.95岁,糖尿病病史为8.81±5.97年,体重指数26.24±2.16kg/m2,血常规、肝功能、肾功能、尿酸在正常范围,TNF-α、IL-6、CRP均有不同程度的升高。
(2)本研究60例2型糖尿病患者其并发症及伴发疾病前3位为高血压病(40%),血脂异常、糖尿病神经病变、糖尿病眼病(均占16.7%)及糖尿病肾病(10%)。
(3)本研究2型糖尿病患者证候发生率依次为：肾虚证、气阴两虚、血脉瘀阻证、肝气郁结、湿热内蕴、心神失养、肺胃燥热、血分郁热。
(4)中医证候与实验室指标的相关性分析：X5(胆固醇)与Y8(血脉瘀阻证)二者有相关性,X1(BMI)与Y5(肺胃燥热证)二者有相关性,X6(TNF-α)与Yl(肾虚证)二者有相关性。
2.实验研究结果
(1)糖尿病大鼠血糖：降糖补肾方能降低糖尿病大鼠的空腹血糖,降糖补肾方高剂量组降糖效果与阿司匹林组相当(P>0.05)。
(2)糖尿病大鼠血清炎症因子：降糖补肾方高、中、低剂量治疗组均能明显降低血清TNF-α水平,并与阿司匹林组相比差异有统计学意义(P<0.05)；降糖补肾方高、中剂量治疗组能明显降低血清IL-6水平,并与阿司匹林组效果相当；降糖补肾方高、中、低剂量治疗组均能明显降低血清CRP平,并与阿司匹林组相比差异有统计学意义(P<0.01)。
(3)糖尿病大鼠肌肉组织InsR磷酸化、IRS-1酪氨酸磷酸化蛋白印迹检测结果：模型组糖尿病大鼠肌肉组织InsR的磷酸化水平下降,与空白对照组比较差异有统计学意义(P<0.01),降糖补肾低剂量组与阿司匹林组相比P>0.05,说明在改善糖尿病大鼠肌肉组织InsR磷酸化水平方面这两组效果相当。模型组糖尿病大鼠肌肉组织IRS-1的酪氨酸磷酸化下降,与空白对照组比较差异有统计学意义(P<0.01),阿司匹林组、降糖补肾高剂量组与空白对照组相比(P>0.05),说明阿司匹林组、降糖补肾高剂量组能显著改善IRS-1酪氨酸磷酸化水平,两组效果相当(P>0.05)。
(4)糖尿病大鼠大腿肌肉组织IKK β mRNA表达水平：模型组IKK β mRNA表达明显高于空白对照组,是空白对照组的5.0983倍,阿司匹林组、降糖补肾方高剂量组能明显降低IKK β mRNA表达,分别是空白对照组的2.8144、3.2464倍；降糖补肾方中、低剂量组能降低IKK β mRNA表达,分别是空白对照组的3.7705、4.974倍。
结论：
1.临床研究
2型糖尿病患者以中老年多见,大多体形肥胖、血脂紊乱。2型糖尿病并发症及伴发疾病多见高血压病、血脂异常、糖尿病神经病变、糖尿病眼病及糖尿病肾病。2型糖尿病患者血清TNF-α、IL-6、CRP均有不同程度的升高。2型糖尿病为本虚标实之证,本虚证以肾虚及气阴两虚为主要表现,标实证以血瘀、气郁、湿热为主。在2型糖尿病实验室指标与中医证候研究中发现,胆固醇与血脉瘀阻证二者有相关性,BMI与肺胃燥热证二有相关性；TNF-α与肾虚证二者有相关性。
2.实验研究
降糖补肾方可显著降低糖尿病模型大鼠的空腹血糖及血清TNF-α、IL-6、CRP水平,可以抑制糖尿病大鼠肌肉组织IKK β mRNA表达,增加糖尿病大鼠肌肉组织InsR磷酸化、IRS-1酪氨酸磷酸化白蛋表达,其机制可能与降糖补肾方抑制了炎症信号通路的转导,从而发挥其改善胰岛素抵抗及治疗糖尿病的作用有关。
Background
Prevalence of adult diabetes in our country over the age of20was9.7%, the total number of adults with diabetes in China reached92.4million, approximately90%for type2diabetes mellitus (T2DM).Diabetes has become a major public health problem. Chinese medicine as early as the LingSHU(?)WuBianPian Kidney good disease elimination hate the record,that this disease occurred in the kidney is closely related to, or said that the kidney is a key factor in diabetes incidence.Inflammation hypothesis of diabetes are recognized by more and more industry experts and scholars in recent years in the understanding of Western medicine. T2DM is a chronic, subclinical inflammatory disease,many pro-inflammatory factor, double-stranded RNA and viruses by acting on the IKKβ caused by insulin resistance(IR) and islet β-cell apoptosis,leading to T2DM. IKKβ has become a new pharmacological target of prevention and treatment of T2DM study, inhibition of IKKβ activity can prevent the development of T2DM and its complications.
Previous studies showed that traditional Chinese medicine compound the Jiangtang Bushen Recipe has the effect of clearing away heat and efficacy of clinical treatment of T2DM, and confirmed the order to inhibit the inflammatory response. The purpose of this study was to understand the clinical features of type2diabetes and metabolic characteristics,summary of type2diabetes Syndromes TCM syndromes and analysis the correlation of inflammatory markers and other laboratory parameters, to understand the material basis of traditional Chinese medicine syndrome. And on the basis of pre-clinical studies,in-depth to explore the mechanism of the Jiangtang Bushen Recipe treatment of T2DM,start from the source of the role of inflammatory cytokines IKKβ/NF-κ B pathway to observe the the hypoglycemic kidney side pathway links IKKβ expression and activity in rats. The research may clear hypoglycemic specific role of Jiangtang Bushen Recipe, the results will be possible to develop for T2DM inflammation of the biological effects of target prevention and treatment of T2DM in Chinese medicine new drugs,resulting in the objective economic and social benefits.
Objectives
1.Type2diabetes-related literature to understand the present Western understanding of the doctrine of inflammation in type2diabetes,Systematic reviews of clinical efficacy and safety of the domestic biomedical journals published Bushenhuoxue class traditional Chinese medicine treatment of type2diabetes.
2. Clinical surveillance to the clinical features of type2diabetes and metabolic characteristics,and summarize the Syndromes of type2diabetes, understanding the material basis of traditional Chinese medicine with type2diabetes syndrome.
3.Experimental study to understand the efficacy of traditional Chinese medicine hypoglycemic kidney side and the specific role of the link.
Methods
1.Literature research
Western medicine in recent years,the understanding of type2diabetes inflammation hypothesis literature review, by computer search of the clinical research literature database～the domestic biomedical journals published in May2011for the treatment of type2diabetes Chinese medicine Bushenhuoxue law and its clinical efficacy and safety of the system evaluation.
2. Clinical research
60cases,the Guangdong Provincial Hospital of Endocrinology outpatient and endocrine ward patients with type2diabetes in March2011to June2011, to collect the patient's general demographic data, and Western-related indicators,indicator of inflammatory factors,complications and concomitant diseases and TCM syndrome score, to EPIdata3.1package to establish a database for statistical analysis, spss17.0.
3. Experimental research
Prepared diabetic rats with high fat diet+small dose of streptozotocin by intraperitoneal injection into a mold in rats randomly assigned to the appropriate intervention, and the rats in each group, detect blood glucose levels of rats in each group, serum levels of inflammatory factors, muscle tissue IKKβ mRNA expression and protein levels of InsR phosphorylation of IRS-1tyrosine phosphorylation protein levels, with spss17.0packages for statistical analysis.
Results
1.The result of clinical research
(1)60patients with type2diabetes patients with an average age of61.20±12.95years of age,history of diabetes was8.81±5.97years,body mass index26.24±2.16kg/m2,blood, liver function, renal function, uric acid in the normal range, the TNF-α,IL-6, CRP increased in varying degrees.
(2)60cases of type2diabetes patients with complications and diseases associated with the first three is hypertension(40%),dyslipidemia, diabetic neuropathy, diabetic eye disease (account for16.7%)and diabetic nephropathy(10%).
(3)In this study, patients with type2diabetes syndrome incidence as follows:kidney deficiency syndrome,Qi and Yin deficiency blood stasis,Liver Qi Stagnation, damp, mind dystrophy, lung and stomach hot,Blood swelter.
(4)Canonical analysis of TCM Syndrome Correlation with laboratory indexes:the X5(cholesterol)and Y8(blood stasis)related,X1(BMI) and Y5(hot lung and stomach)between correlation;X6(TNF-alpha)and Y1(kidney deficiency syndrome)between the correlation.
2. The result of experimental research
(1)The result of fasting blood glucose (FBG) showed that the Jangtang Bushen Recipe can reduce FBG of diabetic rats,the FBG of high-dose of Jiangtang Bushen Recipe group and aspirin group showed a no difference (P>0.05).
(2)The Jangtang Bushen Recipe of high,medium and low-dose group can significantly reduce serum TNF-α levels, and significant difference(P<0.05) compared with the aspirin group;the Jangtang Bushen Recipe of high and medium dose group can significantly reduce the serum IL-6level,with the aspirin group and the effect is quite;the Jangtang Bushen Recipe of high, medium and low-dose group could significantly reduce serum CRP levels and a significant difference(P<0.01) compared with the aspirin group
(3) The result of Western blotting method showed that protein activity of InsR phosphorylation in muscle tissue of diabetic rats comparison between the model group and control group showed a significant difference(P<0.01), the protein activity of InsR phosphorylation in muscle tissue of diabetic rats comparison between low-dose of Jiangtang Bushen Recipe group and aspirin group showed a no difference (P>0.05),and the2groups are on the same level.The protein activity of IRS-1tyrosine phosphorylation in muscle tissue of diabetic rats comparison between the model group and control group showed a significant difference (P<0.01),the protein activity of IRS-1tyrosine phosphorylation in muscle tissue of diabetic rats comparison with high-dose of Jiangtang Bushen Recipe group, aspirin group and control group showed a no difference (P>0.05),the high-dose of Jiangtang Bushen Recipe group and aspirin group are on the same level (P>0.05)
(4) RT-PCR shows that the model group is5.098times higher than blank control group in improving expression of IKKβ mRNA (P<0.01), but the group of Aspirin is2.814times,high-dose group of Jiangtang Bushen recipe is3.246times,medium-dose group of Jiangtang Bushen recipe is3.770times higher than the blank control group in decreasing.compared to model group P<0.01; low-dose group of Jiangtang Bushen recipe is4.974times higher than the blank control group in decreasing.compared to model group P>0.05.
Conclusion
1.Clinical research
Type2diabetes is more common in middle-aged, mostly body obesity, dyslipidemia. Type2diabetes complications and concomitant diseases prevalent hypertension, dyslipidemia, diabetic neuropathy, diabetic eye disease and diabetic nephropathy.Type2diabetic patients serum levels of TNF-alpha, IL-6, CRP, in varying degrees rise.Type2diabetes is deficiency of Ben and repletion of Biao, this deficiency in order to kidney and Qiyinliangxu, mainly standard empirical blood stasis, qi,damp, mainly. In the laboratory markers of type2diabetes and TCM syndrome research found that cholesterol and blood stasis,BMI and lung and stomach hot, TNF-α and kidney deficiency syndrome both correlation.
2.Experimental research
Jangtang Bushen Recipe significantly reduce fasting blood glucose and serum TNF-alpha, IL-6, CRP levels in diabetic rats,can inhibit muscle tissue of diabetic rats IKKβmRNA expression, increase in muscle tissue of diabetic rats InsR phosphorylation of IRS-1tyrosine phosphorylation in the expression of white eggs, its mechanism may be inhibition of the inflammatory signal transduction pathway with hypoglycemic kidney side, to play to the role of improving insulin resistance and treatment of diabetes.
前期的研究表明,中药复方降糖补肾方有补肾健脾,养阴清热之功效,临床治疗T2DM疗效较好,并证实该方能抑制炎症反应。本研究旨在了解2型糖尿病的临床特点及代谢特点,总结2型糖尿病的证候规律,对中医证候与炎症指标及其他实验室指标进行相关性分析,了解中医证候的物质基础。并在前期临床研究的基础上,深入探讨降糖补肾方治疗T2DM的作用机理,从炎症细胞因子作用的源头IKKβ/NF-κB通路入手,观察降糖补肾方对此通路的关键环节IKKβ表达及活性的干预作用。这一研究可能明确降糖补肾方具体作用环节,研究结果将为针对T2DM炎症生物效应靶点可能开发出预防和治疗T2DM的中药新药,从而产生客观的经济和社会效益。
目的：
1.通过2型糖尿病的相关文献研究,了解目前中西医对2型糖尿病炎症学说的认识,系统评价国内生物医学类期刊发表的补肾活血类中药复方治疗2型糖尿病的临床疗效及安全性。
2.通过临床观察了解2型糖尿病的临床特点及代谢特点,总结2型糖尿病的证候规律,了解2型糖尿病中医证候的物质基础。
3.通过实验研究了解中药复方降糖补肾方的疗效及具体作用环节。
方法：
1.文献研究
对近年来中西医对2型糖尿病炎症学说的认识进行文献综述,通过计算机检索建库-2011年5月国内生物医学类期刊发表的有关中医药补肾活血法治疗2型糖尿病的临床研究文献并对其临床疗效及安全性进行系统评价。
2.临床研究
广东省中医院内分泌科2011年3月至2011年6月门诊和内分泌科病房的2型糖尿病患者60例,搜集患者的一般人口学资料、西医相关指标、炎症因子指标、并发症及伴发疾病情况及中医证候积分,采用EPIdata3.1软件包建立数据库,spss17.0进行统计分析。
3.实验研究
采用高脂饲料喂养+小剂量链脲佐菌素腹腔注射的方法制备糖尿病大鼠模型,成模大鼠随机分组,并对各组大鼠予相应干预,检测各组大鼠的血糖水平、血清炎症因子水平、糖尿病大鼠肌肉组织的IKK β mRNA表达及糖尿病大鼠肌肉组织的InsR磷酸化蛋白水平、IRS-1酪氨酸磷酸化蛋白水平,采用spssl7.0软件包进行统计分析。
结果：
1.临床研究结果
(1)60例2型糖尿病患者的平均年龄为61.20±12.95岁,糖尿病病史为8.81±5.97年,体重指数26.24±2.16kg/m2,血常规、肝功能、肾功能、尿酸在正常范围,TNF-α、IL-6、CRP均有不同程度的升高。
(2)本研究60例2型糖尿病患者其并发症及伴发疾病前3位为高血压病(40%),血脂异常、糖尿病神经病变、糖尿病眼病(均占16.7%)及糖尿病肾病(10%)。
(3)本研究2型糖尿病患者证候发生率依次为：肾虚证、气阴两虚、血脉瘀阻证、肝气郁结、湿热内蕴、心神失养、肺胃燥热、血分郁热。
(4)中医证候与实验室指标的相关性分析：X5(胆固醇)与Y8(血脉瘀阻证)二者有相关性,X1(BMI)与Y5(肺胃燥热证)二者有相关性,X6(TNF-α)与Yl(肾虚证)二者有相关性。
2.实验研究结果
(1)糖尿病大鼠血糖：降糖补肾方能降低糖尿病大鼠的空腹血糖,降糖补肾方高剂量组降糖效果与阿司匹林组相当(P>0.05)。
(2)糖尿病大鼠血清炎症因子：降糖补肾方高、中、低剂量治疗组均能明显降低血清TNF-α水平,并与阿司匹林组相比差异有统计学意义(P<0.05)；降糖补肾方高、中剂量治疗组能明显降低血清IL-6水平,并与阿司匹林组效果相当；降糖补肾方高、中、低剂量治疗组均能明显降低血清CRP平,并与阿司匹林组相比差异有统计学意义(P<0.01)。
(3)糖尿病大鼠肌肉组织InsR磷酸化、IRS-1酪氨酸磷酸化蛋白印迹检测结果：模型组糖尿病大鼠肌肉组织InsR的磷酸化水平下降,与空白对照组比较差异有统计学意义(P<0.01),降糖补肾低剂量组与阿司匹林组相比P>0.05,说明在改善糖尿病大鼠肌肉组织InsR磷酸化水平方面这两组效果相当。模型组糖尿病大鼠肌肉组织IRS-1的酪氨酸磷酸化下降,与空白对照组比较差异有统计学意义(P<0.01),阿司匹林组、降糖补肾高剂量组与空白对照组相比(P>0.05),说明阿司匹林组、降糖补肾高剂量组能显著改善IRS-1酪氨酸磷酸化水平,两组效果相当(P>0.05)。
(4)糖尿病大鼠大腿肌肉组织IKK β mRNA表达水平：模型组IKK β mRNA表达明显高于空白对照组,是空白对照组的5.0983倍,阿司匹林组、降糖补肾方高剂量组能明显降低IKK β mRNA表达,分别是空白对照组的2.8144、3.2464倍；降糖补肾方中、低剂量组能降低IKK β mRNA表达,分别是空白对照组的3.7705、4.974倍。
结论：
1.临床研究
2型糖尿病患者以中老年多见,大多体形肥胖、血脂紊乱。2型糖尿病并发症及伴发疾病多见高血压病、血脂异常、糖尿病神经病变、糖尿病眼病及糖尿病肾病。2型糖尿病患者血清TNF-α、IL-6、CRP均有不同程度的升高。2型糖尿病为本虚标实之证,本虚证以肾虚及气阴两虚为主要表现,标实证以血瘀、气郁、湿热为主。在2型糖尿病实验室指标与中医证候研究中发现,胆固醇与血脉瘀阻证二者有相关性,BMI与肺胃燥热证二有相关性；TNF-α与肾虚证二者有相关性。
2.实验研究
降糖补肾方可显著降低糖尿病模型大鼠的空腹血糖及血清TNF-α、IL-6、CRP水平,可以抑制糖尿病大鼠肌肉组织IKK β mRNA表达,增加糖尿病大鼠肌肉组织InsR磷酸化、IRS-1酪氨酸磷酸化白蛋表达,其机制可能与降糖补肾方抑制了炎症信号通路的转导,从而发挥其改善胰岛素抵抗及治疗糖尿病的作用有关。
Background
Prevalence of adult diabetes in our country over the age of20was9.7%, the total number of adults with diabetes in China reached92.4million, approximately90%for type2diabetes mellitus (T2DM).Diabetes has become a major public health problem. Chinese medicine as early as the LingSHU(?)WuBianPian Kidney good disease elimination hate the record,that this disease occurred in the kidney is closely related to, or said that the kidney is a key factor in diabetes incidence.Inflammation hypothesis of diabetes are recognized by more and more industry experts and scholars in recent years in the understanding of Western medicine. T2DM is a chronic, subclinical inflammatory disease,many pro-inflammatory factor, double-stranded RNA and viruses by acting on the IKKβ caused by insulin resistance(IR) and islet β-cell apoptosis,leading to T2DM. IKKβ has become a new pharmacological target of prevention and treatment of T2DM study, inhibition of IKKβ activity can prevent the development of T2DM and its complications.
Previous studies showed that traditional Chinese medicine compound the Jiangtang Bushen Recipe has the effect of clearing away heat and efficacy of clinical treatment of T2DM, and confirmed the order to inhibit the inflammatory response. The purpose of this study was to understand the clinical features of type2diabetes and metabolic characteristics,summary of type2diabetes Syndromes TCM syndromes and analysis the correlation of inflammatory markers and other laboratory parameters, to understand the material basis of traditional Chinese medicine syndrome. And on the basis of pre-clinical studies,in-depth to explore the mechanism of the Jiangtang Bushen Recipe treatment of T2DM,start from the source of the role of inflammatory cytokines IKKβ/NF-κ B pathway to observe the the hypoglycemic kidney side pathway links IKKβ expression and activity in rats. The research may clear hypoglycemic specific role of Jiangtang Bushen Recipe, the results will be possible to develop for T2DM inflammation of the biological effects of target prevention and treatment of T2DM in Chinese medicine new drugs,resulting in the objective economic and social benefits.
Objectives
1.Type2diabetes-related literature to understand the present Western understanding of the doctrine of inflammation in type2diabetes,Systematic reviews of clinical efficacy and safety of the domestic biomedical journals published Bushenhuoxue class traditional Chinese medicine treatment of type2diabetes.
2. Clinical surveillance to the clinical features of type2diabetes and metabolic characteristics,and summarize the Syndromes of type2diabetes, understanding the material basis of traditional Chinese medicine with type2diabetes syndrome.
3.Experimental study to understand the efficacy of traditional Chinese medicine hypoglycemic kidney side and the specific role of the link.
Methods
1.Literature research
Western medicine in recent years,the understanding of type2diabetes inflammation hypothesis literature review, by computer search of the clinical research literature database～the domestic biomedical journals published in May2011for the treatment of type2diabetes Chinese medicine Bushenhuoxue law and its clinical efficacy and safety of the system evaluation.
2. Clinical research
60cases,the Guangdong Provincial Hospital of Endocrinology outpatient and endocrine ward patients with type2diabetes in March2011to June2011, to collect the patient's general demographic data, and Western-related indicators,indicator of inflammatory factors,complications and concomitant diseases and TCM syndrome score, to EPIdata3.1package to establish a database for statistical analysis, spss17.0.
3. Experimental research
Prepared diabetic rats with high fat diet+small dose of streptozotocin by intraperitoneal injection into a mold in rats randomly assigned to the appropriate intervention, and the rats in each group, detect blood glucose levels of rats in each group, serum levels of inflammatory factors, muscle tissue IKKβ mRNA expression and protein levels of InsR phosphorylation of IRS-1tyrosine phosphorylation protein levels, with spss17.0packages for statistical analysis.
Results
1.The result of clinical research
(1)60patients with type2diabetes patients with an average age of61.20±12.95years of age,history of diabetes was8.81±5.97years,body mass index26.24±2.16kg/m2,blood, liver function, renal function, uric acid in the normal range, the TNF-α,IL-6, CRP increased in varying degrees.
(2)60cases of type2diabetes patients with complications and diseases associated with the first three is hypertension(40%),dyslipidemia, diabetic neuropathy, diabetic eye disease (account for16.7%)and diabetic nephropathy(10%).
(3)In this study, patients with type2diabetes syndrome incidence as follows:kidney deficiency syndrome,Qi and Yin deficiency blood stasis,Liver Qi Stagnation, damp, mind dystrophy, lung and stomach hot,Blood swelter.
(4)Canonical analysis of TCM Syndrome Correlation with laboratory indexes:the X5(cholesterol)and Y8(blood stasis)related,X1(BMI) and Y5(hot lung and stomach)between correlation;X6(TNF-alpha)and Y1(kidney deficiency syndrome)between the correlation.
2. The result of experimental research
(1)The result of fasting blood glucose (FBG) showed that the Jangtang Bushen Recipe can reduce FBG of diabetic rats,the FBG of high-dose of Jiangtang Bushen Recipe group and aspirin group showed a no difference (P>0.05).
(2)The Jangtang Bushen Recipe of high,medium and low-dose group can significantly reduce serum TNF-α levels, and significant difference(P<0.05) compared with the aspirin group;the Jangtang Bushen Recipe of high and medium dose group can significantly reduce the serum IL-6level,with the aspirin group and the effect is quite;the Jangtang Bushen Recipe of high, medium and low-dose group could significantly reduce serum CRP levels and a significant difference(P<0.01) compared with the aspirin group
(3) The result of Western blotting method showed that protein activity of InsR phosphorylation in muscle tissue of diabetic rats comparison between the model group and control group showed a significant difference(P<0.01), the protein activity of InsR phosphorylation in muscle tissue of diabetic rats comparison between low-dose of Jiangtang Bushen Recipe group and aspirin group showed a no difference (P>0.05),and the2groups are on the same level.The protein activity of IRS-1tyrosine phosphorylation in muscle tissue of diabetic rats comparison between the model group and control group showed a significant difference (P<0.01),the protein activity of IRS-1tyrosine phosphorylation in muscle tissue of diabetic rats comparison with high-dose of Jiangtang Bushen Recipe group, aspirin group and control group showed a no difference (P>0.05),the high-dose of Jiangtang Bushen Recipe group and aspirin group are on the same level (P>0.05)
(4) RT-PCR shows that the model group is5.098times higher than blank control group in improving expression of IKKβ mRNA (P<0.01), but the group of Aspirin is2.814times,high-dose group of Jiangtang Bushen recipe is3.246times,medium-dose group of Jiangtang Bushen recipe is3.770times higher than the blank control group in decreasing.compared to model group P<0.01; low-dose group of Jiangtang Bushen recipe is4.974times higher than the blank control group in decreasing.compared to model group P>0.05.
Conclusion
1.Clinical research
Type2diabetes is more common in middle-aged, mostly body obesity, dyslipidemia. Type2diabetes complications and concomitant diseases prevalent hypertension, dyslipidemia, diabetic neuropathy, diabetic eye disease and diabetic nephropathy.Type2diabetic patients serum levels of TNF-alpha, IL-6, CRP, in varying degrees rise.Type2diabetes is deficiency of Ben and repletion of Biao, this deficiency in order to kidney and Qiyinliangxu, mainly standard empirical blood stasis, qi,damp, mainly. In the laboratory markers of type2diabetes and TCM syndrome research found that cholesterol and blood stasis,BMI and lung and stomach hot, TNF-α and kidney deficiency syndrome both correlation.
2.Experimental research
Jangtang Bushen Recipe significantly reduce fasting blood glucose and serum TNF-alpha, IL-6, CRP levels in diabetic rats,can inhibit muscle tissue of diabetic rats IKKβmRNA expression, increase in muscle tissue of diabetic rats InsR phosphorylation of IRS-1tyrosine phosphorylation in the expression of white eggs, its mechanism may be inhibition of the inflammatory signal transduction pathway with hypoglycemic kidney side, to play to the role of improving insulin resistance and treatment of diabetes.
引文
[1]中华医学会糖尿病学分会,2010中国糖尿病防治指南。北京大学医学出版社,2011.5：1.
[2]Duncan B, Schmidt M I, Pankow J S, et al.Low grade systemic inflammation and the development of type 2 diabetes:The atherosclerosis risk in communities study[J]. Diabetes,2003,52(7):1799-1805.
[3]Cai D, Yuan M, Frantz D F, et al. Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappa B[J].Nat MED,2005,11(2):183-190.
[4]Freeman D J,Norrie J,Caslake M J,et al.C-reactive protein is an independent predictor of risk for the development of diabetes in the west of Scotland Cornory Prevention Study [J].Diabetes,2002,51(5):1596-1600.
[5]Hu F B,Meigs J B,Li T Y,et al. Inflammatory markers and risk of developing type 2 diabetes in women[J], Diabetes,2004,53(3):693-700.
[6]宋全超,王思宏.2型糖尿病患者C反应蛋白与下肢血管病变的关系[J]。工企医刊,2011,6：6-7.
[7]吴晓燕,汤旭磊等.2型糖尿病免疫炎症的初步探讨[J]。中国免疫学杂志,2007,23(10)：944-946.
[8]蒙延胜,张兵,赵英梅,等.2型糖尿病胰岛素抵抗与多项血清因子水平的相关性分析[J]。中国医药导报,2011,8(5)：159-160.
[9]Feata A, D'Agostino R, Jr, Tracy R P et al.Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes:the insulin resistance atherosclerosis study[J].Diabetes,2002,51(4):1131-1137.
[10]滕顺文,韦燕,张绍峰,等.脂联素对2型糖尿病患者心血管并发症的影响[J]。华夏医学,2011.24(4)：417-419.
[11]王辉,肖新华,鄢盛凯,等.2型糖尿病患者血清脂联素、瘦素和游离脂肪酸与代谢及炎症因子的相关性[J]。基础医学与临床,2006,26(5)：503-507.
[12]许林鑫,史国良,杨静.2型糖尿病患者血清瘦素水平及相关性分析[J]。山西医科大学学报,2011.42(11)：903-905.
[13]Wouters E F. Local and systemic inflammation in chronic obstructive pulmonary disease[J].Proc Am Thorac Soc,2005,2(1):26-33.
[14]Li W G, Gavrlia D, Liu X, et al.Ghrelin inhibits proinflammatory responses and nuclear factor-kappa B activation in human endothelial cells[J]. Circulation,2004, 109(8):2221-2226.
[15]Walder K, Kantham I, Mcmillan J S, et al.Tanis:a link between type 2 diabetes and inflammation[J] Diabetes,2002,51(6):1859-1866.
[16]段亚平,金仲品。Tanis与胰岛素抵抗[J]。生命的化学,2005,25(3)：241-243.
[17]Sizemore N, Lerner N, Dombrowski N, Sakurai H, et al.Distinct roles of the I kappa B kinase alpha and beta subunits in liberating nuclear factor kappa B (NF kappa B) from I kappa B and in phosphorylating the p65 subunit of NF-kappa B. J Biol Chem,2002;277: 3863-3869
[18]Huber MA, Denk A, Peter RU, et al.The IKK-2/Ikappa Balpha/NF-kappa B pathway plays a key role in the regulation of CCR3 and eotaxin-1 in fibroblasts. A critical link to dermatitis in Ikappa Balpha-deficient mice. J Biol Chem,2002,277:1268-1275.
[19]黄文林,朱孝峰主编.《信号转导》,[M]第一版,人民卫生出版社,2005：138
[20]Melloul D. Role of NF-kappaB in beta-cell death[J].Biochem Soc Trans,2008,36(3): 334-339.
[21]Yuan M, Konstantopoulos N, Lee J, et al. Reversal of obesity-and diet-induced insulin resistance with salicylates or targeted disruption of Ikkbeta. Science 2001:293:1673-1677.
[22]Fleischman A, Shoelson SE, Bernier R, Goldfine AB. Salsalate improves glycemia and inflammatory parameters in obese young adults. Diabetes Care 2008;31:289-294.
[23]Hundal RS, Petersen KF, Mayerson AB, et al.Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes[J].J Clin Invest,2002, 109(10):1321-1326.
[24]Hirosumi J, Tuncman G, Chang L, et al.A central role for JNK in obesity and insulin resistance[J].Nature,2002,420(6913):333-336.
[25]Liu G, Rondinone CM. JNK:bridging the insulin signaling and inflammatory pathway[J]. Curr Opin Investing Drugs,2005,6(10):979-987.
[26]Kaneto H, Nakatani Y, Miyatsuka T, et al. Possible novel therapy for diabetes with cell-permeable JNK-inhibitory pep tide [J]. Nat Med,2004,10(10):1128-1132.
[27]Nakamura T, Kawagoe Y, Ogawa H, et al. Effect of low-density lipoprotein aphaeresis on urinary protein and podocyte excretion in patients with nephritic syndrome due to diabetic nephropathy[J]. Am J Kidney Dis,2005,45(1):48-53.
[28]Vincent J A, Mohr S. Inhibition of caspase-1/interleukin-1 beta signaling prevents degeneration of retinal capillaries in diabetes and galactosemia[J].Diabetes,2007, 56(1):224-230.
[29]Demiran N, Safran B G, Soylu M, et al. Determination of vitreous interleukin-1(IL-1)and tumor necrosis factor(TNF)levels in pro-liferative diabetic retinopathy[J].Eye,2006,20(12):1366-1369.
[30]Ugochukwu N H, Figgers C L. Caloric restriction inhibits up-regulation of inflammatory cytokines and TNF-alpna、and activates il-10 and haptoglobin in the plasma of streptozotocin-induced diabetic rats[J].J Nutr Biochem,2007,18(2):120-126.
[31]Hilgendroff A, Muth H, Parviz B, et al.Statins differ in their ability to block NF-kappaB activation in human blood monocytes[J].Int J Clin Pharmacol Ther, 2003,41(9):397-401.
[32]Riad A, Du J, Stiehl S, et al. Low-dose treatment with atorvastatin leads to anti-oxidative and anti-inflammatory effects in diabetes mellitus[J].Eur J Pharmacol, 2007,569(3):204-211.
[33]Isoda K, Young J, Zirlik A, et al.Metformin inhibits proinflammatory responses and nuclear factor-kappaB in human vascular wall cells[J].Arterioscler Thromb Vasc Biol,2006,26(3):611-617.
[34]Kowluru R A, Kanwar M. Effects of curcumin on retinal oxidative stress and inflammation in diabetes[J].Nutr Metab(Lond),2007,16(4):8.
[35]黄忠宁,黄杜茹,尹东明,等.2型糖尿病黄斑病变的相关因素分析[J]。新医学,2004,35(11)：675-676.
[36]倪青.中西贯通燮因理圆机活法巧辨治—辨治糖尿病的经验述要[J]。辽宁中医杂志,2000,27(1)：3-5.
[37]崔振华,温双兰,魏秋林.2型糖尿病辨治思路刍议[J]。河北中医,2000,22(4)：279.
[38]徐进华,马雅玲.Ⅱ型糖尿病患者中医辨证分型与垂体—肾上腺轴激素的关系研究[J]。放射免疫学杂志,2000,13(3)：141-142.
[39]叶任高.内科学[M]。第5版,北京：人民卫生出版社,2000.272,798.
[40]王静芳.96例老年糖尿病中医证候分析[J]。上海中医杂志,1999,7：21-22.
[41]潘明政,李玲.糖尿斌患者中医证候特点及其相关因素探讨[J]。北京中医药大学学报,2006,7(13)6-12.
[42]谭从娥,倪青.基于多元统计分析的糖尿病肾虚证得分布特征研究[J]。时珍国医国药,2010.21(9)2360-2362.
[43]吴昆仑.六味地黄丸药理研究及临床应用新进展[J].中成药,2005,27(11)：16-18.
[44]张金玉.六味地黄丸治疗糖尿病肾病40例[J].中国民间疗法,2006,14(4)：45-46.
[45]孙林琳.六味地黄丸治疗糖尿病患者牙周炎的疗效观察[J].中国现代医药杂志,2007,9(1)：9-10.
[46]王霞,余江毅.中药对早前2型糖尿病炎症因子影响的研究[J]。现代中西医结合杂志,2007,3(16)8：1017.
[47]胡伟,喻嵘.左归复方对MKR小鼠血糖血脂及炎症因子CRP、IL-6、TNF-α的影响[J]。湖南中医药大学学报,2009,4(29)2：16
[48]黄河清,黄俊.金匮肾气丸加味治疗气阴两虚Ⅱ型糖尿病[J].新中医,2005,27(9)：39-40.
[49]王文,买成德,马志有.益气温阳法治疗2型糖尿病阳虚型30例疗效观察[J].宁夏医学杂志,2003,25(12)：775.
[50]李磊,孙大华.老年性糖尿病脾肾两虚证得中西医结合防治研究。第九次全国中西医结合虚证与老年病学术会议论文集,2008,8：119-121.
[51]陈利平,朱章志.健脾益气方对脾气虚证2型糖尿病大鼠血清炎症因子的影响[J]。中药新药与临床药理,2009,1(20)1：37
[52]陈小燕,李芹.益气补肾活血汤治疗肾虚血瘀型糖尿病血液流变学的影响[J].福建中医药,2002,33(5)：12-13.
[53]张春华.糖尿病从肾虚痰瘀论治浅析[J].实用中医内科,2005,19(6)：533.
[54]徐丽君,曾凡鹏,陆付耳,等.补肾通脉方对2型糖尿病大鼠骨骼肌胰岛素受体表达的影响[J].中国医院药学杂志,2003,23(4)：201-203.
[55]范冠杰,唐咸玉。降糖补肾方对2型糖尿病患者血清CRP、IL-6及TNF-α的影响[J]。中国中西医结合杂志,2006,4(26)4：330.
[56]Jadad AR, Moore A, Carroll D, Jenkinson C, Reynolds JM, Gavaghan DJ. Assessing the quality of reports of randomized clinical trials:Is blinding necessary [J].Control Clin Trials,1996;17(1):1-12.
[57]张琳,王翼洲,高健.补肾化瘀冲剂治疗老年2型糖尿病30例-附对照组26例[J].辽宁中医杂志,1995,22(3)：128-129.
[58]顾小侠.补肾祛瘀治疗老年性糖尿病(Ⅱ型)探究[J].中国乡村医生杂志,1999,10：41-42.
[59]孙元波,孙元萍.理气活血补肾方治疗2型糖尿病52例[J].北京中医,1999,2：41.
[60]宋宗良,文汉英,李元祥.降糖汤治疗2型糖尿病48例[J].陕西中医学院学报,2001,24(4)：16-17.
[61]郭清华.益气养阴补肾活血法治疗2型糖尿病85例[J].光明中医,2003,18(105)：50-51.
[62]朱健萍,巩如伦.益肾活血汤治疗2型糖尿病的临床观察[J].天津中医药,2006,23(5)：377-379.
[63]钱玉良.益肾健脾活血汤治疗Ⅱ型糖尿病72例临床观察[J].湖南中医杂志,1999,15(1)：7-9.
[64]祁颖欣.益肾降糖方治疗2型糖尿病67例[J].甘肃中医,2006,19(6)：17-18.
[65]焦英霞,董秀荣,姜琪.西黄降糖胶囊治疗2型糖尿病87例临床观察[J].中医药学报,2003,31(4)：41-43.
[66]仇年芳.滋阴活血补肾法治疗老年2型糖尿病32例临床观察[J].现代临床医学,2006,32(5)：353-354.
[67]钱秋海,李玉忠,庄乾竹.三黄消渴胶囊治疗老年糖尿病的临床研究[J].中国实验方剂学杂志,2002,8(4)：48-50.
[68]黄煌,刘汉胜,杨小春等.滋阴益肾降糖治疗Ⅱ型糖尿病的临床观察[J].新疆中医药,2005,23(3)：24-25.
[69]陈玉碧,张宏.补肾活血片对Ⅱ型糖尿病患者过氧化脂质、血脂及血糖的影响[J].中国中西医结合杂志,1995,15(11)：661-663.
[70]申涛,郭赛珊,梁晓春.中药仙贞片对气阴两虚兼肾虚血瘀2型糖尿病患者红细胞变形性的影响[J].中国中西医结合杂志,1998,18(7)：405-407.
[71]徐波,卢进宝,田丰华.自拟益气滋肾化瘀汤治疗Ⅱ型糖尿病50例[J].中原医刊,2000,27(7)：20-21.
[72]杨文英,邢晓燕,林红,等.高甘油三酯血症是非胰岛素依赖型糖尿病发病的危险因素——432例非糖尿病人群六年前瞻性观察[J].中华内科杂志.1995,34：583.
[73]许樟荣,王玉珍,敬华,等.血脂紊乱和糖尿病大血管并发症以及胰岛素抵抗[J].中国医学科学院学报,2002,24：457-461.
[74]Livak KJ, Sehmittgen TD.Analysis of relative gene expression data Using real-time quantitative PCR and the 2(-Delta Delta C(T))Method[J]. Methods,2001,25(4): 402-408.
[75]卫琼玲,石渊渊,等.地骨皮的降血糖机制研究[J].中草药,2005,36(7)：1050-1052.
[76]方志伟,刘非,等.地骨皮降血糖作用的实验研究[J].中医药学报,2004,32(4)：47-48.
[77]周晶,孟林,等.地骨皮对四氧嚓陡糖尿病小鼠的降糖作用[J].中成药,2001,23(6)：424-425.
[78]张明.黄连素治疗糖尿病疗效观察[J].湖北中医杂志,2001,23(6)：16.
[79]童金花.黄连素片治疗2型糖尿病49例临床观察[J].新中医,1997,29(3)：33.
[80]闰秀敏,黎明,邢雪林.浅谈黄连素的药理与临床应用[J].中国医药卫生,2005,6(3)：62.
[81]陈蔚,刘芳,俞茂华,等.黄芪多糖对NOD小鼠Ⅰ型糖尿病的预防作用[J].复旦学报(医学 科学版),2001,28(1)：57-60.
[82]毛淑梅,李承德,等.黄芪注射液对链脲佐菌素诱导的Ⅰ型糖尿病大鼠血清TNF-a含量的影响[J].中医药临床杂志,2008,20(3)：248-249.
[83]鲁瑾,邹大进,张家庆,等.黄芪预防肿瘤坏死因子所致胰岛素抵抗的影响[J].中国中西医结合杂志,1999,19(7)：420-422.
[84]李春梅,高永林,等.知母皂普对小鼠血糖的影响[J].中药药理与临床2005,21(4)：22-23.
[85]刘竹青,张克良,麻风华,等.葛根煎剂对糖尿病大鼠降血糖机理的研究[J].中医药信息,2006,23(3)：56-58.
[86]白红艳,邹文俊,高小平,等.葛根对地塞米松诱导的胰岛素抵抗的影响[J].中国中药杂志,2004,29(4)：356-358.
[87]韩会民,,王树国.葛根素治疗非胰岛素依赖型糖尿病患者胰岛素抵抗的研究[J].中国中西医结合急救杂志,2006,13(2)：117-119.
[88]李文仕.小檗碱降糖调脂作用机理的研究概况[J].右江民族医学院学报,2008,4：648-649.
[89]闰秀敏,黎明,邢雪林.浅谈黄连素的药理与临床应用[J].中国医药卫生,2005,6(3)：62.
[90]Pan JF,YuC,ZhuDY,al.Identification of three sulfate conju gated metabo lites Of berber inechlor ideinhealthy Vof unteer,surineai roralad stratlon.ActaPha cof Sin(中国药理学报),2002,23(1)：77-82.
[91]汪宁,朱荃,等.桑枝、桑白皮体外降糖作用研究[J].中药药理与临床,2005,21(6)：35-36.
[92]李春梅,高永林,等.知母皂普对小鼠血糖的影响[J].中药药理与临床2005;21(4)：22-23.
[93]黄芳,徐丽华,等.知母提取物的降血糖作用[J].中国生化药物杂志,2005,26(6)：332-335.
[94]YouH J, Ch oiC Y,Ki mJ Y, et al.Ur solica cide nhancesn itric oxide and tumorn ecrosisfa ctor-alphap roduction via nuclear factor-kappaB activation in the restingm acrophages [J].FEBSL et.2001,509(2):156-160.
[95]Liu J. Pharmacology of oleanolic acid and ursolic acid[J].JE thnopharmacol.19 95,49(2):57-68.
[96]杨莉,叶真.地骨皮对2型糖尿病大鼠肾病的防治作用与机制研究[J].中华中医药学刊,2008,26(10)：2172-2175.
[2]Duncan B, Schmidt M I, Pankow J S, et al.Low grade systemic inflammation and the development of type 2 diabetes:The atherosclerosis risk in communities study[J]. Diabetes,2003,52(7):1799-1805.
[3]Cai D, Yuan M, Frantz D F, et al. Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappa B[J].Nat MED,2005,11(2):183-190.
[4]Freeman D J,Norrie J,Caslake M J,et al.C-reactive protein is an independent predictor of risk for the development of diabetes in the west of Scotland Cornory Prevention Study [J].Diabetes,2002,51(5):1596-1600.
[5]Hu F B,Meigs J B,Li T Y,et al. Inflammatory markers and risk of developing type 2 diabetes in women[J], Diabetes,2004,53(3):693-700.
[6]宋全超,王思宏.2型糖尿病患者C反应蛋白与下肢血管病变的关系[J]。工企医刊,2011,6：6-7.
[7]吴晓燕,汤旭磊等.2型糖尿病免疫炎症的初步探讨[J]。中国免疫学杂志,2007,23(10)：944-946.
[8]蒙延胜,张兵,赵英梅,等.2型糖尿病胰岛素抵抗与多项血清因子水平的相关性分析[J]。中国医药导报,2011,8(5)：159-160.
[9]Feata A, D'Agostino R, Jr, Tracy R P et al.Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes:the insulin resistance atherosclerosis study[J].Diabetes,2002,51(4):1131-1137.
[10]滕顺文,韦燕,张绍峰,等.脂联素对2型糖尿病患者心血管并发症的影响[J]。华夏医学,2011.24(4)：417-419.
[11]王辉,肖新华,鄢盛凯,等.2型糖尿病患者血清脂联素、瘦素和游离脂肪酸与代谢及炎症因子的相关性[J]。基础医学与临床,2006,26(5)：503-507.
[12]许林鑫,史国良,杨静.2型糖尿病患者血清瘦素水平及相关性分析[J]。山西医科大学学报,2011.42(11)：903-905.
[13]Wouters E F. Local and systemic inflammation in chronic obstructive pulmonary disease[J].Proc Am Thorac Soc,2005,2(1):26-33.
[14]Li W G, Gavrlia D, Liu X, et al.Ghrelin inhibits proinflammatory responses and nuclear factor-kappa B activation in human endothelial cells[J]. Circulation,2004, 109(8):2221-2226.
[15]Walder K, Kantham I, Mcmillan J S, et al.Tanis:a link between type 2 diabetes and inflammation[J] Diabetes,2002,51(6):1859-1866.
[16]段亚平,金仲品。Tanis与胰岛素抵抗[J]。生命的化学,2005,25(3)：241-243.
[17]Sizemore N, Lerner N, Dombrowski N, Sakurai H, et al.Distinct roles of the I kappa B kinase alpha and beta subunits in liberating nuclear factor kappa B (NF kappa B) from I kappa B and in phosphorylating the p65 subunit of NF-kappa B. J Biol Chem,2002;277: 3863-3869
[18]Huber MA, Denk A, Peter RU, et al.The IKK-2/Ikappa Balpha/NF-kappa B pathway plays a key role in the regulation of CCR3 and eotaxin-1 in fibroblasts. A critical link to dermatitis in Ikappa Balpha-deficient mice. J Biol Chem,2002,277:1268-1275.
[19]黄文林,朱孝峰主编.《信号转导》,[M]第一版,人民卫生出版社,2005：138
[20]Melloul D. Role of NF-kappaB in beta-cell death[J].Biochem Soc Trans,2008,36(3): 334-339.
[21]Yuan M, Konstantopoulos N, Lee J, et al. Reversal of obesity-and diet-induced insulin resistance with salicylates or targeted disruption of Ikkbeta. Science 2001:293:1673-1677.
[22]Fleischman A, Shoelson SE, Bernier R, Goldfine AB. Salsalate improves glycemia and inflammatory parameters in obese young adults. Diabetes Care 2008;31:289-294.
[23]Hundal RS, Petersen KF, Mayerson AB, et al.Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes[J].J Clin Invest,2002, 109(10):1321-1326.
[24]Hirosumi J, Tuncman G, Chang L, et al.A central role for JNK in obesity and insulin resistance[J].Nature,2002,420(6913):333-336.
[25]Liu G, Rondinone CM. JNK:bridging the insulin signaling and inflammatory pathway[J]. Curr Opin Investing Drugs,2005,6(10):979-987.
[26]Kaneto H, Nakatani Y, Miyatsuka T, et al. Possible novel therapy for diabetes with cell-permeable JNK-inhibitory pep tide [J]. Nat Med,2004,10(10):1128-1132.
[27]Nakamura T, Kawagoe Y, Ogawa H, et al. Effect of low-density lipoprotein aphaeresis on urinary protein and podocyte excretion in patients with nephritic syndrome due to diabetic nephropathy[J]. Am J Kidney Dis,2005,45(1):48-53.
[28]Vincent J A, Mohr S. Inhibition of caspase-1/interleukin-1 beta signaling prevents degeneration of retinal capillaries in diabetes and galactosemia[J].Diabetes,2007, 56(1):224-230.
[29]Demiran N, Safran B G, Soylu M, et al. Determination of vitreous interleukin-1(IL-1)and tumor necrosis factor(TNF)levels in pro-liferative diabetic retinopathy[J].Eye,2006,20(12):1366-1369.
[30]Ugochukwu N H, Figgers C L. Caloric restriction inhibits up-regulation of inflammatory cytokines and TNF-alpna、and activates il-10 and haptoglobin in the plasma of streptozotocin-induced diabetic rats[J].J Nutr Biochem,2007,18(2):120-126.
[31]Hilgendroff A, Muth H, Parviz B, et al.Statins differ in their ability to block NF-kappaB activation in human blood monocytes[J].Int J Clin Pharmacol Ther, 2003,41(9):397-401.
[32]Riad A, Du J, Stiehl S, et al. Low-dose treatment with atorvastatin leads to anti-oxidative and anti-inflammatory effects in diabetes mellitus[J].Eur J Pharmacol, 2007,569(3):204-211.
[33]Isoda K, Young J, Zirlik A, et al.Metformin inhibits proinflammatory responses and nuclear factor-kappaB in human vascular wall cells[J].Arterioscler Thromb Vasc Biol,2006,26(3):611-617.
[34]Kowluru R A, Kanwar M. Effects of curcumin on retinal oxidative stress and inflammation in diabetes[J].Nutr Metab(Lond),2007,16(4):8.
[35]黄忠宁,黄杜茹,尹东明,等.2型糖尿病黄斑病变的相关因素分析[J]。新医学,2004,35(11)：675-676.
[36]倪青.中西贯通燮因理圆机活法巧辨治—辨治糖尿病的经验述要[J]。辽宁中医杂志,2000,27(1)：3-5.
[37]崔振华,温双兰,魏秋林.2型糖尿病辨治思路刍议[J]。河北中医,2000,22(4)：279.
[38]徐进华,马雅玲.Ⅱ型糖尿病患者中医辨证分型与垂体—肾上腺轴激素的关系研究[J]。放射免疫学杂志,2000,13(3)：141-142.
[39]叶任高.内科学[M]。第5版,北京：人民卫生出版社,2000.272,798.
[40]王静芳.96例老年糖尿病中医证候分析[J]。上海中医杂志,1999,7：21-22.
[41]潘明政,李玲.糖尿斌患者中医证候特点及其相关因素探讨[J]。北京中医药大学学报,2006,7(13)6-12.
[42]谭从娥,倪青.基于多元统计分析的糖尿病肾虚证得分布特征研究[J]。时珍国医国药,2010.21(9)2360-2362.
[43]吴昆仑.六味地黄丸药理研究及临床应用新进展[J].中成药,2005,27(11)：16-18.
[44]张金玉.六味地黄丸治疗糖尿病肾病40例[J].中国民间疗法,2006,14(4)：45-46.
[45]孙林琳.六味地黄丸治疗糖尿病患者牙周炎的疗效观察[J].中国现代医药杂志,2007,9(1)：9-10.
[46]王霞,余江毅.中药对早前2型糖尿病炎症因子影响的研究[J]。现代中西医结合杂志,2007,3(16)8：1017.
[47]胡伟,喻嵘.左归复方对MKR小鼠血糖血脂及炎症因子CRP、IL-6、TNF-α的影响[J]。湖南中医药大学学报,2009,4(29)2：16
[48]黄河清,黄俊.金匮肾气丸加味治疗气阴两虚Ⅱ型糖尿病[J].新中医,2005,27(9)：39-40.
[49]王文,买成德,马志有.益气温阳法治疗2型糖尿病阳虚型30例疗效观察[J].宁夏医学杂志,2003,25(12)：775.
[50]李磊,孙大华.老年性糖尿病脾肾两虚证得中西医结合防治研究。第九次全国中西医结合虚证与老年病学术会议论文集,2008,8：119-121.
[51]陈利平,朱章志.健脾益气方对脾气虚证2型糖尿病大鼠血清炎症因子的影响[J]。中药新药与临床药理,2009,1(20)1：37
[52]陈小燕,李芹.益气补肾活血汤治疗肾虚血瘀型糖尿病血液流变学的影响[J].福建中医药,2002,33(5)：12-13.
[53]张春华.糖尿病从肾虚痰瘀论治浅析[J].实用中医内科,2005,19(6)：533.
[54]徐丽君,曾凡鹏,陆付耳,等.补肾通脉方对2型糖尿病大鼠骨骼肌胰岛素受体表达的影响[J].中国医院药学杂志,2003,23(4)：201-203.
[55]范冠杰,唐咸玉。降糖补肾方对2型糖尿病患者血清CRP、IL-6及TNF-α的影响[J]。中国中西医结合杂志,2006,4(26)4：330.
[56]Jadad AR, Moore A, Carroll D, Jenkinson C, Reynolds JM, Gavaghan DJ. Assessing the quality of reports of randomized clinical trials:Is blinding necessary [J].Control Clin Trials,1996;17(1):1-12.
[57]张琳,王翼洲,高健.补肾化瘀冲剂治疗老年2型糖尿病30例-附对照组26例[J].辽宁中医杂志,1995,22(3)：128-129.
[58]顾小侠.补肾祛瘀治疗老年性糖尿病(Ⅱ型)探究[J].中国乡村医生杂志,1999,10：41-42.
[59]孙元波,孙元萍.理气活血补肾方治疗2型糖尿病52例[J].北京中医,1999,2：41.
[60]宋宗良,文汉英,李元祥.降糖汤治疗2型糖尿病48例[J].陕西中医学院学报,2001,24(4)：16-17.
[61]郭清华.益气养阴补肾活血法治疗2型糖尿病85例[J].光明中医,2003,18(105)：50-51.
[62]朱健萍,巩如伦.益肾活血汤治疗2型糖尿病的临床观察[J].天津中医药,2006,23(5)：377-379.
[63]钱玉良.益肾健脾活血汤治疗Ⅱ型糖尿病72例临床观察[J].湖南中医杂志,1999,15(1)：7-9.
[64]祁颖欣.益肾降糖方治疗2型糖尿病67例[J].甘肃中医,2006,19(6)：17-18.
[65]焦英霞,董秀荣,姜琪.西黄降糖胶囊治疗2型糖尿病87例临床观察[J].中医药学报,2003,31(4)：41-43.
[66]仇年芳.滋阴活血补肾法治疗老年2型糖尿病32例临床观察[J].现代临床医学,2006,32(5)：353-354.
[67]钱秋海,李玉忠,庄乾竹.三黄消渴胶囊治疗老年糖尿病的临床研究[J].中国实验方剂学杂志,2002,8(4)：48-50.
[68]黄煌,刘汉胜,杨小春等.滋阴益肾降糖治疗Ⅱ型糖尿病的临床观察[J].新疆中医药,2005,23(3)：24-25.
[69]陈玉碧,张宏.补肾活血片对Ⅱ型糖尿病患者过氧化脂质、血脂及血糖的影响[J].中国中西医结合杂志,1995,15(11)：661-663.
[70]申涛,郭赛珊,梁晓春.中药仙贞片对气阴两虚兼肾虚血瘀2型糖尿病患者红细胞变形性的影响[J].中国中西医结合杂志,1998,18(7)：405-407.
[71]徐波,卢进宝,田丰华.自拟益气滋肾化瘀汤治疗Ⅱ型糖尿病50例[J].中原医刊,2000,27(7)：20-21.
[72]杨文英,邢晓燕,林红,等.高甘油三酯血症是非胰岛素依赖型糖尿病发病的危险因素——432例非糖尿病人群六年前瞻性观察[J].中华内科杂志.1995,34：583.
[73]许樟荣,王玉珍,敬华,等.血脂紊乱和糖尿病大血管并发症以及胰岛素抵抗[J].中国医学科学院学报,2002,24：457-461.
[74]Livak KJ, Sehmittgen TD.Analysis of relative gene expression data Using real-time quantitative PCR and the 2(-Delta Delta C(T))Method[J]. Methods,2001,25(4): 402-408.
[75]卫琼玲,石渊渊,等.地骨皮的降血糖机制研究[J].中草药,2005,36(7)：1050-1052.
[76]方志伟,刘非,等.地骨皮降血糖作用的实验研究[J].中医药学报,2004,32(4)：47-48.
[77]周晶,孟林,等.地骨皮对四氧嚓陡糖尿病小鼠的降糖作用[J].中成药,2001,23(6)：424-425.
[78]张明.黄连素治疗糖尿病疗效观察[J].湖北中医杂志,2001,23(6)：16.
[79]童金花.黄连素片治疗2型糖尿病49例临床观察[J].新中医,1997,29(3)：33.
[80]闰秀敏,黎明,邢雪林.浅谈黄连素的药理与临床应用[J].中国医药卫生,2005,6(3)：62.
[81]陈蔚,刘芳,俞茂华,等.黄芪多糖对NOD小鼠Ⅰ型糖尿病的预防作用[J].复旦学报(医学 科学版),2001,28(1)：57-60.
[82]毛淑梅,李承德,等.黄芪注射液对链脲佐菌素诱导的Ⅰ型糖尿病大鼠血清TNF-a含量的影响[J].中医药临床杂志,2008,20(3)：248-249.
[83]鲁瑾,邹大进,张家庆,等.黄芪预防肿瘤坏死因子所致胰岛素抵抗的影响[J].中国中西医结合杂志,1999,19(7)：420-422.
[84]李春梅,高永林,等.知母皂普对小鼠血糖的影响[J].中药药理与临床2005,21(4)：22-23.
[85]刘竹青,张克良,麻风华,等.葛根煎剂对糖尿病大鼠降血糖机理的研究[J].中医药信息,2006,23(3)：56-58.
[86]白红艳,邹文俊,高小平,等.葛根对地塞米松诱导的胰岛素抵抗的影响[J].中国中药杂志,2004,29(4)：356-358.
[87]韩会民,,王树国.葛根素治疗非胰岛素依赖型糖尿病患者胰岛素抵抗的研究[J].中国中西医结合急救杂志,2006,13(2)：117-119.
[88]李文仕.小檗碱降糖调脂作用机理的研究概况[J].右江民族医学院学报,2008,4：648-649.
[89]闰秀敏,黎明,邢雪林.浅谈黄连素的药理与临床应用[J].中国医药卫生,2005,6(3)：62.
[90]Pan JF,YuC,ZhuDY,al.Identification of three sulfate conju gated metabo lites Of berber inechlor ideinhealthy Vof unteer,surineai roralad stratlon.ActaPha cof Sin(中国药理学报),2002,23(1)：77-82.
[91]汪宁,朱荃,等.桑枝、桑白皮体外降糖作用研究[J].中药药理与临床,2005,21(6)：35-36.
[92]李春梅,高永林,等.知母皂普对小鼠血糖的影响[J].中药药理与临床2005;21(4)：22-23.
[93]黄芳,徐丽华,等.知母提取物的降血糖作用[J].中国生化药物杂志,2005,26(6)：332-335.
[94]YouH J, Ch oiC Y,Ki mJ Y, et al.Ur solica cide nhancesn itric oxide and tumorn ecrosisfa ctor-alphap roduction via nuclear factor-kappaB activation in the restingm acrophages [J].FEBSL et.2001,509(2):156-160.
[95]Liu J. Pharmacology of oleanolic acid and ursolic acid[J].JE thnopharmacol.19 95,49(2):57-68.
[96]杨莉,叶真.地骨皮对2型糖尿病大鼠肾病的防治作用与机制研究[J].中华中医药学刊,2008,26(10)：2172-2175.